| Name | Title | Contact Details |
|---|---|---|
Ann Tomlin |
Senior Vice President of Human Resources | Profile |
Joann Scubelek-Prushinski |
Regional Sales Director | Profile |
Pegah Rabby |
VP of Finance | Profile |
Capri Pavlich |
Associate Director Of Marketing | Profile |
Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders.
Genemed Synthesis, Inc. is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Be Biopharma is a leader in developing B cells as medicines, treating disease with the human body`s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, allogeneic, re-dosable, and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., Be Biopharma is re-imagining medicine based on the power of B cell therapy. Be Bio was founded in October 2020 by Longwood Fund with a $52 million Series A investment led by Atlas Ventures and RA Capital, joined by Alta Partners and Takeda Ventures.
Aphios Corp is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
YmAbs has a powerful set of capabilities for the development of biologics. Our product development team includes some of the most talented and experienced professionals in the antibody industry.